Zydus Cadila receives USFDA’s final approval for mesalamine delayed–release tablets
DSIJ Intelligence / 25 Jul 2017
The group has received 27 final ANDA approvals from the USFDA and 2 tentative ANDA approvals since January 2017.
has received the Final approval has been received by Zydus Cadila from the USFDA for Mesalamine delayed-release tablets in the strength of 800 mg, the company said in a BSE filing on Tuesday.
The group’s formulation manufacturing facility at Moraiya will be manufacturing the drug. The group has received 27 final ANDA approvals from the USFDA and 2 tentative ANDA approvals since January 2017.
The group now has more than 130 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04, the company filing added.
At Rs 547.55, Cadila Healthcare was trading up by Rs 15.90 or 2.99% as of 1425 hours on Tuesday, on the BSE.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.